



S18 Fig. Weighted linear correlation between overall survival and progression-free survival in multicenter cohort.

References

1. Gregory RK, Powles TJ, Chang JC, Ashley S. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. *Eur J Cancer*. 1997;33:2194-7.
2. Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. *N Engl J Med*. 1991;325:1342-8.
3. Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as

first-line chemotherapy: KCSG-BR07-02. *J Clin Oncol*. 2013;31:1732-9.

4. Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. *Eur J Cancer*. 1993;29A:527-31.
5. Tredan O, Follana P, Moullet I, Cropet C, Trager-Maury S, Dauba J, et al. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. *Ann Oncol*. 2016;27:1020-9.
6. Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. *Breast Cancer Res Treat*. 2010;122:169-76.
7. Coates A, Gebiski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. *N Engl J Med*. 1987;317:1490-5.
8. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. *J Clin Oncol*. 1998;16:1669-76.
9. French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. *J Clin Oncol*. 2000;18:3115-24.
10. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. *J Clin Oncol*. 2006;24:3912-8.
11. Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2014;15:1351-60.
12. Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, et al.

Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. *Lancet*. 1990;335:186-90.

13. Mayordomo JI, Baena JM, Cirera L, Sanchez-Rovira P, Godes MJ, Galan A, et al. Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. *J Clin Oncol* 2009; 15 Suppl:1001.

14. Kloke O, Klaassen U, Oberhoff C, Hartwich G, Szanto J, Wolf E, et al. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. *Breast Cancer Res Treat*. 1999;55:51-9.